Cargando…

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Berit Maria, Keil, Elke, Lehmann, Annika, Winzer, Klaus-Jürgen, Richter-Ehrenstein, Christiane, Prinzler, Judith, Bangemann, Nikola, Reles, Angela, Stadie, Sylvia, Schoenegg, Winfried, Eucker, Jan, Schmidt, Marcus, Lippek, Frank, Jöhrens, Korinna, Pahl, Stefan, Sinn, Bruno Valentin, Budczies, Jan, Dietel, Manfred, Denkert, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694878/ https://www.ncbi.nlm.nih.gov/pubmed/23826382 http://dx.doi.org/10.1371/journal.pone.0068252

Ejemplares similares

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
por: Kronenwett, Ralf, et al.
Publicado: (2012)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort
por: Somashekhar, S. P., et al.
Publicado: (2020)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2020)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015)

Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia
por: Von Laffert, Maximilian, et al.
Publicado: (2016)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study
por: Budczies, Jan, et al.
Publicado: (2012)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
por: Budczies, Jan, et al.
Publicado: (2012)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview
por: Jöhrens, Korinna, et al.
Publicado: (2021)

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
por: Lehmann, Annika, et al.
Publicado: (2009)

Possible Estrogen Dependency in the Pathogenesis of Branchial Cleft Cysts
por: Raguse, Jan D., et al.
Publicado: (2017)

New network topology approaches reveal differential correlation patterns in breast cancer
por: Bockmayr, Michael, et al.
Publicado: (2013)

Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
por: Budczies, Jan, et al.
Publicado: (2017)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rvq5o3p3qg73fdp5b9b4s176kh